Cancer, according to the International Agency for Research on
Cancer (IARC) resulted in the death of around 4.6 million men worldwide
in 2012. Around 14% of the world’s total annual deaths are as a result
of various cancers. Modern medicine has extended the life expectancy of a
cancer patient by a great margin. However newer cases are diagnosed
every year globally, the present rate stands at 7.4 million newly
diagnosed males annually, according to the WHO. This is commonly as a
result of the changing lifestyles, unhealthy diet, hereditary factors
and exposure to carcinogenic elements, cigarette smoking, etc. Male
specific cancers include: prostate cancer, testicular cancer, and penile
cancer. Among which prostate cancer is the most prevalent form of male
cancer. Male specific cancers are generally benign/malignant tumors that
rarely undergo metastasis.
Report Overview @ https://www.transparencymarketresearch.com/penile-cancer-market.html
Penile cancers are an even rarer form of cancer specific to the
male reproductive organ i.e. penis, but unlike prostate and testicular
cancer, they are commonly as a result of human papiloma virus (HPV), and
human immunodeficiency virus (HIV) infection. According to the U.S
National Cancer Institute study roughly 40% of all penile cancer is as a
result of HPV infections, whereas HIV patients exhibit eight time
increased risk of penile cancer. Hence penile cancer rates are high in
developing countries of Africa, South Asia and South America. This is
probably why vaccination for HPV virus (Gardasil or Cervarix) is
regarded by a share of expert medical practitioners as a preventive
measure in decreasing penile cancer rates globally. The incidence rate
for penile cacner is found higher in men above 30 years of age, Penile
cancer is majorly categorized as squamous cell carcinoma, as a large
majority of penile cancer patients have exhibited this form. Other even
rare types include intraepithelial neoplasia, bowenoid papulosis and
invasive carcinoma of the penis.
The diagnosis of penile cancer is initially done by physical
examination of the penis, this is followed by the biopsy of the
outgrowth i.e. wart/ papules or skin abscess. Staging of the penile
malignancy is done further to establish a timeline of disease
progression. Chemotherapy, antiviral therapy and surgical excision are
the common mode of treatment for penile cancer. Surgical methods are
classified on the type of procedure apt to remove the tumor;
circumcision, microsurgery, excision, or penectomy (castration) are the
generally followed procedures. Radiation is used to prevent any
reoccurrence, although the procedure can render the patient infertile.
That said, the market for male cancer therapeutics is highly
fragmented hence not easily quantifiable, however the surgery and
overall treatment market remains in millions of USD, with new
diagnostic screening procedures and drug combinations being patented
every year, each having their own market segment. With entry of Asian
players the prices too are bound to decrease, thereby potentially
increasing the overall therapeutics market.
The North American market is the highest market by volume, followed
by Europe, as in these regions the number of reported cases are high in
number, and so is the affordability of drugs. In developing markets of
Asia and South America, their poor hygiene standards, presence of a
large HIV patient population along with their overall increasing
population size make for a large market, however unavailability of
affordable diagnostic procedures and therapeutic drugs is thought to be
the major reason why diagnosis is few in number and why the markets
haven’t been proliferated as of yet. The rest of the world region is
also bound to follow a similar pattern with increased awareness and
diagnostic rates, the number of diagnosed individuals undergoing therapy
in this region is however very small.
Some of the major companies manufacturing HPV vaccines include:
GlaxoSmithKline PLC, Novartis AG, MercK & Co, etc to name a few.
No comments:
Post a Comment